CFTR mutations, the underlying cause of cystic fibrosis (CF), may contribute to CF-related diabetes (CFRD) by directly impairing pancreatic function, independent of mucus buildup, a study suggested. CF patients with residual CFTR protein function responded better to sugar intake than those with minimal CFTR function, as indicated by…
News
People with cystic fibrosis (CF) who show impaired lung ventilation — problems with air moving into and out of the lungs — are more than twice as likely to experience pulmonary exacerbations (PEx) over two years than those with normal ventilation, according to a new study that compared the…
The Driven Brands Collision Group announced it has raised more than $6 million to support care, advocacy, and research related to cystic fibrosis (CF). “This milestone represents the heart of our organization,” Damien Reyna, chief operating officer, collision, for Driven Brands, said in a company press release. “Our…
A new survey conducted in Germany showed that, in addition to easing symptoms and improving quality of life, Trikafta enables most patients with cystic fibrosis (CF) to reduce the use of supportive therapies, according to a study. However, this is being done without clear guidelines. “We think it best…
Researchers in Australia have identified six potential genes that may help explain why people with cystic fibrosis (CF) experience pain — and respond to pain treatments — differently. The genes — CTRC, SPINK1, TNF, ABCB1, PRSS1, and TGFB1 — were found to interact with CFTR, the gene whose mutations…
The experimental inhaled gene therapy 4D-710 showed acceptable safety and signs of improving lung function in adults with cystic fibrosis (CF), according to new Phase 1 clinical trial data. Developer 4D Molecular Therapeutics (4DMT) has now selected the study’s lowest dose for further evaluation in a Phase 2…
People with cystic fibrosis (CF) who lost weight while taking GLP-1 receptor agonists (GLP-1 RAs) — medications commonly used for diabetes and weight loss — saw their lung function improve, a small U.S. study found. While more studies are needed to determine whether these drugs are safe for CF…
ETD001, Enterprise Therapeutics’ inhaled investigational therapy to improve mucus clearance in people with cystic fibrosis (CF) — regardless of the underlying CF-causing mutation — was well tolerated in healthy individuals at doses higher than those predicted to be therapeutic, a study showed. The now-complete Phase 1…
Biomx is ending a Phase 2b trial of BX004, its investigational nebulized phage therapy for Pseudomonas aeruginosa infection in people with cystic fibrosis (CF). The move comes on the heels of a safety review of the trial (NCT06998043) conducted by an independent data monitoring committee, which…
After starting treatment with Trikafta, people with cystic fibrosis (CF) tend to have less need for inhaled mucus-clearing therapies and antibiotics, according to a new analysis of data from a real-world study. Moreover, the reduced need for other medication while on Trikafta was found to continue over the…
Your CF Community
Visit the Cystic Fibrosis News Today forums to connect with others in the CF community.